News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Lynn M. Schuchter: Dr. Bertagnolli is the ideal leader for NIH and I enthusiastically endorse and urge the Senate to confirm her.
Photo from Lynn M. Schuchter/Twitter
Oct 19, 2023, 17:21

Lynn M. Schuchter: Dr. Bertagnolli is the ideal leader for NIH and I enthusiastically endorse and urge the Senate to confirm her.

Lynn M. Schuchter shared on Twitter:

“Amazing testimony by Dr. Monica Bertagnolli during yesterday’s Senate confirmation hearing to be NIH Director. Hearing included thoughtful discussion on obesity epidemic, rural healthcare access, inflammation in disease, disparities in care, clinical trial diversity and more.

These are also issues we prioritize at ASCO because everyone deserves access to high quality, affordable and equitable care. Dr. Bertagnolli is the ideal leader for NIH and I enthusiastically endorse and urge the Senate to confirm her.”

Source: Lynn M. Schuchter/Twitter

Lynn M. Schuchter is the President of the American Society of Clinical Oncology (ASCO). Dr. Schuchter is the Chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, Director of the Tara Miller Melanoma Center and Professor of Hematology-Oncology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012, as well as several ASCO committees, including terms as Chair of the Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee. In 2019, she was awarded ASCO’s Women Who Conquer Cancer Mentorship Award.

ASCO cancer Headlines Lynn M. Schuchter Monica Bertagnolli NIH OncoDaily Oncology
Insight
Dec 9, 2023, 04:44
President Biden: It's good for the millions of Americans who can't afford their medications
Blog
Dec 9, 2023, 00:38
Thomas Hofmarcher: This is what a great panel discussion looks like!
Blog
Dec 9, 2023, 00:32
Zhiheng Xu: It's not just about how much statistics you know
Blog
Dec 9, 2023, 00:23
Priscilla Chan: Mark and I wrote our annual letter this year about how some of our earliest bets in science are letting us take advantage of this moment in AI
Blog
Dec 9, 2023, 00:18
David Fajgenbaum: 1 in 10 of us will develop a disease with no treatments
Career
Dec 8, 2023, 17:54
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Drugs
Dec 8, 2023, 17:50
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
Drugs
Dec 8, 2023, 17:46
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Insight
Dec 8, 2023, 17:40
Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
Career
Dec 8, 2023, 17:35
Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
Insight
Dec 8, 2023, 17:32
Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
Blog
Dec 8, 2023, 17:27
Tedros Adhanom Ghebreyesus: Gaza cannot afford to lose any more hospitals…
Insight
Positive
Societies
Career